Ixovex-1 Single Agent and Combination Therapy
A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Psivac Ltd, now recruiting.
Overview
Ixovex-1 Single Agent and Combination Therapy is a phase 1/2 interventional study registered as NCT06549946 by Psivac Ltd, with 18 participants planned, started 2024-12-17 and due to reach its primary completion in 2027-01-30. Interventions recorded: Ixovex-1 and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Shares IQVIA and the tag pipeline.
- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialTo Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
Shares Head and neck squamous cell carcinoma and the tag pipeline.